GET DAILY SIGNALSWhy Is Genius Sports Limited (GENI) Stock Down -2.87% Today?
Key Takeaways
- Shares of GENI fell about 2.9% in Friday's session, extending a sharp post-earnings selloff that began a day earlier.
- The decline follows a roughly 15.5% plunge on November 5 after the company reported third-quarter results, closing at $5.92 versus the prior close of $7.01.
- Primary catalyst: a GAAP bottom-line miss (a loss of $0.06 per share versus a roughly breakeven consensus), which overshadowed a revenue beat and raised full-year guidance.
- Secondary drivers: an Oppenheimer price-target cut, concerns about elevated leverage from the Legend acquisition, and regulatory uncertainty around prediction markets.
- Investors are now weighing the company's growth in betting, media, and prediction markets against rising interest costs and a still-unprofitable bottom line.
- Traders are watching technical support levels and any follow-through analyst commentary after the earnings-driven re-rating.
- For more detail, explore Price Targets, Earnings, and Forecast pages for GENI.
- Interested in automated trading ideas? Browse the curated Trending AI Robots section.
Opening Summary
Genius Sports Limited (GENI) is a London-headquartered provider of sports data, technology, and AI-powered services to the sports, sports betting, and sports media industries. In Friday's session, the stock traded lower by roughly 2.9%, hovering around $5.74 to $5.75 after closing the previous session at $5.92. The move marks a continuation of the market's negative reaction to the company's third-quarter earnings, reported before the open on November 5, which triggered a steep single-day decline of approximately 15.5%.
Earnings-Driven Selloff Extends
The dominant catalyst behind the slide is the company's third-quarter 2026 report. Genius Sports posted a GAAP net loss of $0.06 per share, missing the consensus estimate of roughly breakeven, even as revenue of $269.86 million beat expectations of about $260.94 million and grew 62% year over year. The company also delivered its first quarter of positive operating income ($10.4 million), generated roughly $54 million of free cash flow, and expanded adjusted EBITDA margin to about 32%.
Despite these operational milestones and a raised full-year outlook — now calling for revenue of $1.015 billion to $1.035 billion and adjusted EBITDA of $287 million to $297 million — investors focused on the bottom-line miss and the cost of the company's debt-funded growth strategy.
Leverage and Financing Costs
A key concern weighing on GENI shares is the interest burden tied to its acquisition of Legend, a digital sports and gaming media network. Net interest expense surged to roughly $19.1 million in the quarter from near zero a year earlier, reflecting the debt taken on to fund the deal. This financing cost absorbs a significant portion of the company's operating gains before they reach shareholders, keeping the company unprofitable on a net basis even as operating income turned positive.
Analyst Reaction and Price-Target Cut
Following the results, Oppenheimer lowered its price target on GENI to $10 from $12 while maintaining an Outperform rating. The firm cited management's decision to hold fourth-quarter guidance steady despite heightened expectations around prediction-market advertising. The downward revision added to selling pressure and reinforced the cautious tone among investors reassessing near-term growth visibility.
Regulatory Uncertainty in Prediction Markets
Prediction markets have become a central growth narrative for Genius Sports, with partnerships involving Kalshi and Polymarket and the launch of Prediction.com. However, this opportunity carries regulatory risk, including a pending Supreme Court decision and state-level taxation proposals. Management has argued the company is positioned to benefit regardless of how oversight evolves, but the uncertainty contributes to investor caution and adds volatility to the stock.
Market Context and Trading Activity
Trading volume has been significantly elevated. On November 5, more than 21 million shares changed hands, roughly three times the average daily volume of about 6.5 million, underscoring the intensity of the post-earnings reaction. Friday's continued decline suggests investors are still repositioning after the re-rating rather than responding to a distinct new headline. The move reflects stock-specific dynamics tied to earnings, leverage, and regulation, with the broader market playing a secondary role. Shares remain well below their 50-day moving average and near the lower end of a 52-week range of roughly $3.83 to $11.57.
What Comes Next for GENI
Looking ahead, investors will monitor the company's execution on its raised full-year guidance, progress in integrating Legend, and any developments in the prediction-market regulatory landscape, including the pending Supreme Court case and state taxation initiatives. The trajectory of free cash flow and deleveraging will also be closely watched, given the company's higher interest costs. Analyst sentiment remains broadly positive on a price-target basis, but near-term volatility is likely to persist as the market digests the earnings reaction and recalibrates expectations for the fourth quarter and 2027.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron offers hundreds of automated trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Exploring the page can help traders identify automated approaches aligned with today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for GENI shows an upward move is likely
GENI's Aroon Indicator triggered a bullish signal on October 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator showed a similar pattern. In 179 of the 186 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GENI just turned positive on October 06, 2026. Looking at past instances where GENI's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
GENI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 59 cases where GENI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GENI as a result. In 71 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
GENI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.316) is normal, around the industry mean (1.054). P/E Ratio (-8.836) is within average values for comparable stocks, (-35.592). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (17.274). Dividend Yield (0.000) settles around the average of (1.012) among similar stocks. P/S Ratio (2.232) is also within normal values, averaging (71.888).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. GENI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry InternetSoftwareServices
Advertisement